Breaking News

Biogen Licenses Mitsubishi Tanabe’s Phase 2 Molecule for Autoimmune Diseases

Sees potential for development of MT-1303; Mitsubishi to receive $60 million upfront

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen has formed an agreement to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Mitsubishi Tanabe Pharma Corporation. MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor. Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other autoimmune indications. The compound has completed a successful Phase 2 clinical trial in MS and Bio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters